Advanced Search

 

Study ID Status Title Patient Level Data
DRI2440 - Rembrandt Completed A Multicentre, Randomized, Double-Blind, Dose Ranging Study of Org31540/SR90107A in the Initial Treatment of Symptomatic Proximal Deep Vein Thrombosis (DVT)
DRI2643 Completed A multicenter, randomized, parallel, double-blind, dose ranging study of subcutaneous Org31540/SR90107A with an assessor blind, comparative control group of subcutaneous LMWH in the prevention of deep vein thrombosis after elective total hip replacement (Pentathlon).
DRI3196 Completed A multicentre, randomised, dose-ranging study comparing Org31540/SR90107A with heparin as adjunctive therapy to recombinant tissue plasminogen activator and Aspirin in acute myocardial infarction (AMI) (PENTALYSE)
DRI4090 Completed A multicenter, randomized, double-blind, placebo controlled, parallel group, dose response study of subcutaneous Org31540/SR90107A in the prevention of venous thromboembolism after elective total hip replacement surgery.
DRI4757 Completed A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose response study of subcutaneous Org31540/SR90107A in the prevention of venous thromboembolism after elective total knee replacement surgery.
E3870651 Completed A randomised, Two Way Crossover Study to Determine the Time at Which Therapeutic Plasma Concentrations of Paracetamol are Achieved in Two Marketed Formulations
E7411153 Completed An exploratory study to investigate the inflammatory response during a cold sore episode
EFC2441 Completed A multicentre, randomized, double-blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE-DVT)
EFC2442 Completed A multicenter, multinational, randomized, double-blind comparison of subcutaneous Org31540/SR90107A with enoxaparin in the prevention of deep vein thrombosis and symptomatic pulmonary embolism after elective hip replacement or a revision. PENTATHLON 2000
EFC2698 Completed A multicenter, multinational, randomized double-blind comparison study of subcutaneous Org31540/SR90107A versus enoxaparin 40 mg o.d. in the prevention of deep vein thrombosis and symptomatic pulmonary embolism in hip fracture surgery. (PENTHIFRA)
EFC3557 Completed A multicenter, multinational, randomized, double-blind study to compare the efficacy and safety of fondaparinux sodium (Org31540/SR90107A) with dalteparin (Fragmin) in the prevention of venous thromboembolic events in high-risk abdominal surgery (PEGASUS) Study Listed on ClinicalStudyDataRequest.com
EFC4582 Completed A multicenter, multinational, randomized, double-blind study of fondaparinux sodium (Org31540/SR90107A) versus placebo for the prolonged prevention of VTE in hip fracture surgery. (PENTIHFRA PLUS) Study Listed on ClinicalStudyDataRequest.com
EGF 20002 Completed An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens
EGF10001 Completed A Double Blind, Randomized, Placebo-Controlled, Crossover Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Single Oral Escalating Doses Of GW572016 Ditosylate Monohydrate (Lapatinib) In Healthy Volunteers
EGF10002 Completed A Double-Blind, Placebo Controlled, Parallel Study To Investigate The Safety, Tolerability, and Pharmacokinetics of Multiple Oral GW572016 (Lapatinib) Doses In Healthy Subjects
EGF10003 Completed A Phase I, Open-Label, Multiple Dose, Dose-Escalation Study of GW572016 in Patients with Solid Tumors
EGF10004 Completed An Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of Multiple Doses of GW572016 toExamine the Inhibition of ErbB1 (EGFR)/ErbB2 Phosphorylation in Cancer Patients with Solid Tumors
EGF10005 Completed A Phase I, Open-Label Pharmacokinetic Study of the Safety and Tolerability of GW572016 Daily in Combination with Capecitabine on a Three Week Schedule in Patients with Solid Tumors
EGF10008 Completed A Single Dose, Open Label, Randomized, Five-way, Crossover Study in Healthy Subjects to Evaluate the Effect of Food on the Pharmacokinetics of GW572016 and to Evaluate the Relative Bioavailability of GW572016 as a Salt (F) versus Base (X) and Capsule (F) versus Tablet (F)
EGF10009 Completed A Phase I, Open-Label, Study of the Safety, Tolerability, and Pharmacokinetics of GW572016 in Combination with Paclitaxel in Patients with Solid Tumors
EGF10010 Completed A Phase I, Open-Label, Pharmacokinetic Study of the Safety and Tolerability of GW572016 (Lapatinib) in Combination with Oxaliplatin/Fluorouracil/Leucovorin
EGF10011 Completed A Phase I, Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of GW572016 (lapatinib) in Combination with Irinotecan and 5-Fluorouracil/Leucovorin
EGF10012 Completed A Phase I, Open-Label, 4-Period, Crossover Study in Healthy Subjects to Evaluate the Bioequivalence of 2 Oral Tablet Formulations of GW572016 Ditosylate Monohydrate (Lapatinib)
EGF10013 Completed An open-label, two-way randomized crossover study to evaluate the potential inhibition of GW572016 metabolism by ketoconazole
EGF10014 Completed An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of a Single 100mg Oral Dose of Lapatinib in Healthy Subjects and in Subjects with Hepatic Impairment

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.